Aclaris therapeutics, inc. (ACRS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-15,586

-18,594

-55,319

-49,876

-37,565

-38,551

-32,740

-31,218

-30,229

-22,934

-18,192

-14,838

-12,559

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,039

-

-10,632

-2,594

-2,623

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

576

320

1,632

2,231

2,226

958

384

315

222

181

116

55

50

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

21

-

32

22

3

Stock-based compensation expense

3,453

3,181

3,320

4,814

4,862

4,956

4,707

5,249

5,143

4,300

3,673

3,304

3,153

1,910

1,618

1,354

1,222

648

158

42

43

Change in fair value of contingent consideration

1,767

-

-

-

-

406

0

0

866

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash charges related to Vixen acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,784

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-4,737

-12,194

-1,506

3,553

10,956

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-338

650

-1,305

-184

-1,789

-3,421

5,806

-1,323

-1,022

-25

434

1,300

2,597

118

-80

41

-71

505

377

-239

626

Accounts payable

-4,317

-6,210

3,633

-386

-197

1,032

1,239

4,377

316

1,434

-31

2,330

831

895

-1,578

485

2,008

132

-43

-833

385

Accrued expenses

2,227

-8,784

-7,070

5,364

8,523

3,929

1,227

848

788

621

1,154

369

-1,537

460

637

1,314

39

-20

294

262

16

Net cash used in operating activities

-6,805

-20,390

-23,359

-21,378

-31,318

-27,248

-29,858

-21,833

-21,872

-18,210

-13,714

-10,080

-12,659

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,894

-

-10,568

-2,862

-2,802

Purchases of property and equipment

124

266

822

241

284

146

560

352

298

577

270

193

195

62

64

66

40

132

133

165

77

Purchases of marketable securities

8,869

16,082

31,896

16,307

73,100

49,254

38,098

38,632

35,614

76,841

78,962

24,376

17,158

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of marketable securities

22,935

38,600

54,391

35,500

82,000

46,016

49,052

52,270

92,105

55,853

49,022

24,343

23,309

37,261

18,402

21,216

10,214

155

17

5,075

822

Net cash provided by (used in) investing activities

13,942

56,438

21,673

18,952

8,616

-70,506

10,394

13,286

56,193

-21,565

-39,857

-226

5,956

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from debt financing, net of issuance costs

10,950

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Finance lease payments

57

131

152

120

120

149

164

299

36

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,174

-

-13,118

4,910

745

Proceeds from the issuance of stock

25

-

-

-

-

0

183

0

394

0

0

26

209

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

612

664

231

Net cash (used in) provided by financing activities

10,918

-30,009

-70

-117

-120

128,183

19

-299

358

-78

80,918

19,337

209

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

18,055

6,039

-1,756

-2,543

-22,822

30,429

-19,445

-8,846

34,679

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39,252

-664

-231

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-6,494

-

-14,019

18,684

3,280

-15,568

15,566

1,384

-2,288

Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable

16

-83

-185

368

24

59

-340

232

210

254

-170

99

91

-2

-5

-22

40

-

-

-

-

Fair value of stock issued in connection with Confluence acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,355

-

-

-

-

Offering costs included in accounts payable

30

-

-

-

-

190

0

0

20

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease asset recorded as a result of new accounting standard

-

-

-

-

2,132

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

431

676

657